Abdominal Pain

Healio Gastroenterology presents the following report on the top stories from UEG Week 2021.

Assessing meal-related symptoms among patients with disorders of the gut-brain interaction may improve and individualize treatment, according to a presentation at UEG Week Virtual 2021.

New gastrointestinal symptoms among patients with inflammatory bowel disease and COVID-19 did not correlate with an increased risk for death.

Evidence from a systematic review published in American Journal of Gastroenterology showed polyethylene glycol and senna were effective for the treatment of constipation.

More than half of patients with multiple endocrine neoplasia type 2, or MEN2, reported abdominal pain, diarrhea and constipation, and said gastrointestinal symptoms negatively affect their quality of life, according to survey data.

Patients with constipation-predominant irritable bowel syndrome treated with a delayed-release version of linaclotide experienced improvements in abdominal pain, according to study results.

Some complimentary alternative therapies, including herbal and dietary supplements, may help ease abdominal pain and benefit overall response in patients with irritable bowel syndrome, according to study results.

Minesapride, an agonist of 5-hydroxytryptamine 4 receptor, was safe and well-tolerated among patients with constipation-predominant irritable bowel syndrome, according to study results.

Clinical hypnosis that includes focused relaxation and therapeutic suggestion may be a promising complementary therapy for children with Crohn’s disease, according to research from Digestive Disease Week.

Results from a real-word study showed fecal microbiota transplantation for Clostridioides difficile infection was highly effective, with little serious adverse events related to the procedure, according to data from Digestive Disease Week.